1. Shabahang M, Livingstone AS. Cutaneous metastases from a gastrointestinal stromal tumor of the stomach: review of literature. Dig Surg. 2002; 19:64–65.
Article
2. Phan M, Jones S, Jenkins J, Pant S, Khawandanah M. Pancreatic GIST in a patient with limited stage small cell lung cancer: a case report and review of published cases. Case Rep Oncol Med. 2016; 2016:9604982.
Article
3. Yang F, Jin C, Du Z, Subedi S, Jiang Y, Li J, et al. Duodenal gastrointestinal stromal tumor: clinicopathological characteristics, surgical outcomes, long term survival and predictors for adverse outcomes. Am J Surg. 2013; 206:360–367.
Article
4. Lorenzon L, Cavallini M, Balducci G, Frezza B, Fanna M, Caterino S. Surgical strategies for duodenal GISTs: benefits and limitations of minimal resections. Eur J Surg Oncol. 2015; 41:805–807.
Article
5. Kroep JR, Bovée JV, van der, Hogendoorn PC, Gelderblom H. Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. J Cutan Pathol. 2009; 36:565–569.
Article
6. Al-Kalaawy M, El-Zohairy MA, Mostafa A, Al-Kalaawy A, El-Sebae H. Gastrointestinal stromal tumors (GISTs), 10-year experience: patterns of failure and prognostic factors for survival of 127 patients. J Egypt Natl Canc Inst. 2012; 24:31–39.
Article
7. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231:51–58.
8. Wang WL, Hornick JL, Mallipeddi R, Zelger BG, Rother JD, Yang D, et al. Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: a series of 5 cases with molecular analysis. Am J Dermatopathol. 2009; 31:297–300.
Article
9. Hughes B, Yip D, Goldstein D, Waring P, Beshay V, Chong G. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer. 2004; 4:74.
Article
10. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364:1127–1134.
Article